These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34837383)

  • 21. The role of oxidized phospholipids in atherosclerosis.
    Berliner JA; Leitinger N; Tsimikas S
    J Lipid Res; 2009 Apr; 50 Suppl(Suppl):S207-12. PubMed ID: 19059906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JCL roundtable-Lipoprotein(a): The emerging risk factor.
    Marcovina SM; Moriarty PM; Koschinsky ML; Guyton JR
    J Clin Lipidol; 2018; 12(6):1335-1345. PubMed ID: 30527801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis).
    Handa JT; Tagami M; Ebrahimi K; Leibundgut G; Janiak A; Witztum JL; Tsimikas S
    Trans Am Ophthalmol Soc; 2015; 113():T5. PubMed ID: 26538774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations between lipoprotein(a), oxidized phospholipids, and extracoronary vascular disease.
    Bellomo TR; Liu Y; Gilliland TC; Miksenas H; Haidermota S; Wong M; Hu X; Cristino JR; Browne A; Plutzky J; Tsimikas S; Januzzi JL; Natarajan P
    J Lipid Res; 2024 Jun; 65(7):100585. PubMed ID: 38942114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydrogen influences HDL-associated enzymes and reduces oxidized phospholipids levels in rats fed with a high-fat diet.
    Liu B; Zhao M; Xue J; Gu Q; Zhang X; Qin S
    Life Sci; 2021 Feb; 267():118945. PubMed ID: 33359745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on lipoprotein(a) as a cardiovascular risk factor and mediator.
    Boffa MB; Koschinsky ML
    Curr Atheroscler Rep; 2013 Oct; 15(10):360. PubMed ID: 23990263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
    Yeang C; Hung MY; Byun YS; Clopton P; Yang X; Witztum JL; Tsimikas S
    J Clin Lipidol; 2016; 10(3):594-603. PubMed ID: 27206947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An update on lipid oxidation and inflammation in cardiovascular diseases.
    Zhong S; Li L; Shen X; Li Q; Xu W; Wang X; Tao Y; Yin H
    Free Radic Biol Med; 2019 Nov; 144():266-278. PubMed ID: 30946962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pleiotropic effects of oxidized phospholipids.
    Bochkov V; Gesslbauer B; Mauerhofer C; Philippova M; Erne P; Oskolkova OV
    Free Radic Biol Med; 2017 Oct; 111():6-24. PubMed ID: 28027924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Oxidized phospholipids and atherosclerosis].
    Zhao M; Liu BY; Qin SC
    Sheng Li Xue Bao; 2021 Feb; 73(1):69-81. PubMed ID: 33665662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel Therapies for Lipoprotein(a): Update in Cardiovascular Risk Estimation and Treatment.
    Wulff AB; Nordestgaard BG; Langsted A
    Curr Atheroscler Rep; 2024 Apr; 26(4):111-118. PubMed ID: 38311667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice.
    Stulnig TM; Morozzi C; Reindl-Schwaighofer R; Stefanutti C
    Curr Atheroscler Rep; 2019 Jul; 21(10):37. PubMed ID: 31350625
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipoprotein(a) catabolism: a case of multiple receptors.
    McCormick SPA; Schneider WJ
    Pathology; 2019 Feb; 51(2):155-164. PubMed ID: 30595508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin.
    Edelstein C; Philips B; Pfaffinger D; Scanu AM
    FASEB J; 2009 Mar; 23(3):950-6. PubMed ID: 19001055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
    Scipione CA; Koschinsky ML; Boffa MB
    Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive analyses of oxidized phospholipids using a measured MS/MS spectra library.
    Aoyagi R; Ikeda K; Isobe Y; Arita M
    J Lipid Res; 2017 Nov; 58(11):2229-2237. PubMed ID: 28874441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retinal pigment epithelium cells produce VEGF in response to oxidized phospholipids through mechanisms involving ATF4 and protein kinase CK2.
    Pollreisz A; Afonyushkin T; Oskolkova OV; Gruber F; Bochkov VN; Schmidt-Erfurth U
    Exp Eye Res; 2013 Nov; 116():177-84. PubMed ID: 24021586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
    Boffa MB
    Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.